Compare Tencent Music Entertainment Group - ADR (TME) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Tencent Music Entertainment Group - ADR trades at $8.1 (market cap $12.83B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9.9× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tencent Music Entertainment Group - ADR for 67 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TME | VRTX | |
|---|---|---|
Market Cap | $12.83B | $127.55B |
Volume | 3,618,478 | 1,487,944 |
Sector | Media | Health |
52-Week High | $23.71 | $557.96 |
52-Week Low | $7.74 | $407.37 |
Typical Hold Time | 67 Days | 120 Days |
Enterprise Value | $10.77B | $121.68B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TME trades at $7.99, up 0.76% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported strong revenue growth to $32.90 billion in 2025 and a net income of $11.06 billion, with improving profit margins. Recent news highlights a $1 billion notes offering and a $400 million share repurchase program, reflecting financial discipline amid competitive pressures.
The outlook is mixed: valuation ratios like a P/E of 9.33 and P/S of 2.46 suggest potential upside to the $12.50 consensus price target, but risks include slowing user growth and intense competition. Analyst sentiment is cautious with a 'Hold' bias, while cash flow trends show volatility, with a projected recovery in 2026.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
